



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

8 Jun 2020 (#28)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notice

- **[Writing a Winning Application: Conduct a Self-Assessment](#)**. How do you distinguish your application from the rest of the field? Whatever you write in your application is immaterial unless your reviewers deem you able to complete the work you propose.
- **[NOT-OD-20-113](#)**: Findings of Research Misconduct.
- **[NOT-MH-20-058](#)**: Notice of Intent to Publish a Funding Opportunity Announcement for Digital healthcare interventions to address the secondary health effects related to social, behavioral, and economic impact of COVID-19 (R01 - Clinical Trial Optional) The National Institute of Mental Health (NIMH) with other ICs are issuing this Notice of Intent to Publish a Funding Opportunity Announcement to promote new initiatives that will solicit applications to support research to determine the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), wearable devices] to address secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic, particularly among populations who experience health disparities and vulnerable populations. This FOA will utilize the R01 activity code and academic researchers will be required to partner with digital health developers and/or existing well-established digital health delivery platforms to prepare and submit applications. This notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications. Details of the planned FOAs are provided below. This FOA is expected to be published in June 2020 with an expected application due date in July 2020. Application budgets are limited to \$750,000 in direct costs per year for up to three years
- **[NOT-DA-20-004](#)**: Notice of Special Interest (NOSI): Research on Co-morbid Substance Use, Substance Use Disorders, and Other Psychiatric Disorders. The purpose of this Notice is to encourage the submission of research project grant applications that address co-morbid substance use and/or substance use disorders, and other psychiatric disorders.
- **[NOT-DC-20-008](#)** Notice of Special Interest (NOSI): NIDCD is interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders. Coronavirus Disease 2019 (COVID-19) is a recently emerged human disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is a paucity of data on the impact of SARS-CoV-2 on the sensory and communicative functions within the scientific mission areas of NIDCD. NIDCD invites applications for research on COVID-19 in relation to NIDCD's scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL).
- **[NOT-DE-20-006](#)** Notice of Special Interest (NOSI) of NIDCR in Supporting Dental, Oral, and Craniofacial Research Using Bioinformatic, Computational, and Data Science Approaches. The volume, dimension, and complexity of biomedical and behavioral research data are expanding rapidly, requiring bioinformatic, computational, and data science approaches to manage and analyze the data, address new questions, and obtain deeper insight from the data. This Notice of Special Interest (NOSI) calls for research and research training projects that focus on dental, oral, and craniofacial biology and diseases using bioinformatic, computational, and data science approaches.
- **[NOT-MD-20-022](#)** Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations. Related Announcements:
 - [PA-18-591](#), Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

- [PA-18-935](#), Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)
- **[NOT-MH-20-053](#): Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19.** This Notice of Special Interest (NOSI) highlights interest in research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. While the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact.

1. NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-221](#)

Type: DP1

Application Due Date: August 13 2020; August 13, 2021; August 15, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIDA Avant-Garde Award Program for HIV/AIDS Research supports exceptionally creative scientists, who propose high-impact research that will open new areas of HIV/AIDS research in the context of Substance Use Disorders (SUD) and/or lead to new avenues for prevention and treatment of HIV/AIDS in people who use drugs (PWUD). The term “avant-garde” refers to highly innovative ideas and/or approaches that have the potential to be transformative. Applications responding to this FOA must propose research that is substantially different from what is currently being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html>. The NIDA Avant-Garde award supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV/AIDS for PWUD; creative, new strategies to prevent HIV transmission in high-risk drug using populations; novel approaches to improve HIV and HIV-related comorbid disease outcomes; and creative approaches to eradicating HIV and improving the lives of PWUD living with HIV in general.

Budget: NIDA intends to fund 2-3 awards each year. Application budgets are limited to \$700,000 in direct costs per year. The maximum project period allowed is 5 years.

2. Advancing HIV/AIDS Research through Computational Neuroscience FOA (R01 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-21-013](#)

Type: R01

Application Due Date: November 6, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement invites computational HIV/AIDS research as it relates to NIDA’s mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. An R01 research project should build on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD).

Budget: NIDA intends to commit \$2 million in FY 2021 to fund 3-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. Advancing Genomic Medicine Research (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-036](#)

Type: R01

Application Due Date: August 3, 2020; March 8, 2021; November 2, 2021; August 1, 2022; March 13, 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.

Budget: NHGRI intends to fund an estimate of 4 awards, corresponding to a total of \$2,400,000 direct costs, for fiscal year 2021, given sufficient meritorious applications. Future year amounts will depend on annual appropriations. Application budgets allowed up to \$600K direct costs per year, for a project period up to 5 years. Budgets should reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. Advancing Genomic Medicine Research (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-037](#)

Type: R21

Application Due Date: August 3, 2020; March 8, 2021; November 2, 2021; August 1, 2022; March 13, 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.

Budget: NHGRI intends to fund an estimate of 4 awards, corresponding to a total of \$800,000 direct costs, for fiscal year 2021, given sufficient meritorious applications. Future year amounts will depend on annual appropriations. Application budgets allowed up to \$200K direct costs per year, for a project period up to 2 years. Budgets should reflect the actual needs of the proposed project.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105